Kumar Neil's Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Nov 18, 2022
- Accession no.
- 0001209191-22-057985
- Filed
- Nov 18, 2022
- Trade date
- Nov 16-17, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 3 derivative transactions. Open-market sales total $325.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kumar NeilCIK 0001742485 | Director, Officer (CEO and President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2022 | Common Stock | MOption exerciseAcquired | +68,706 | –F1 | – | 4,881,903 | Direct | |
| Nov 16, 2022 | Common Stock | FTax withholdingDisposed | −34,066 | $9.64 | −$328,396.24 | 4,847,837 | Direct | |
| Nov 17, 2022 | Common Stock | SSaleDisposed | −34,640 | $9.40F3 | −$325,616 | 4,813,197 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 16, 2022 | Common Stock | MOption exerciseDisposed | −5,130 | $0.00 | $0 | 30,776 | Direct | |
| Nov 16, 2022 | Common Stock | MOption exerciseDisposed | −2,394 | $0.00 | $0 | 21,548 | Direct | |
| Nov 16, 2022 | Common Stock | MOption exerciseDisposed | −61,182 | $0.00 | $0 | 305,910 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $9.16 to $9.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
Referenced by the price of 1 transaction in Table I.